1 Min Read
May 25 (Reuters) - Abeona Therapeutics Inc
* Abeona Therapeutics receives FDA orphan drug designation for EB-101 gene therapy product for patients with epidermolysis bullosa Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.